Amgen’s Repatha Cholesterol Drug Cuts Risk of Cardiovascular Events in Clinical Trial
24
August

Amgen’s Repatha Cholesterol Drug Cuts Risk of Cardiovascular Events in Clinical Trial

By Adem Lewis / in , , , , /

Here’s the latest on Xtalks.com: Amgen’s cholesterol drug, Repatha, has been shown to cut the risk of cardiovascular events in a recent clinical trial. More detailed results of the study are being presented at the American College of Cardiology 66th Annual Scientific Session. Hello I’m Sarah Hand, Editor and Webinar Moderator for Xtalks.com, and welcome […]